Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Comparative Analysis of Factors Affecting the Prognosis of Patients with Atrial Fibrillation According to the Results of the REKUR-AF Study

https://doi.org/10.20996/1819-6446-2019-15-5-649-655

Full Text:

Abstract

Aim. To conduct a comparative analysis of the significance of the influence of various factors and their combinations on the survival of patients with atrial fibrillation (AF) in the REKUR-AF study.

Material and methods. The database includes 896 patients with AF over 18 years old who applied to medical organizations in the city of Kursk and seven districts of the Kursk region from September 2015 to August 2016. Achievement by the patients of the “end point” (death from any cause) was assessed using a telephone contact for a period of 9.0±0.55 months from the end of the database formation. Data were obtained on 532 patients, of which 60 patients reached the end point. To study the differences in survival in subgroups of patients with different characteristics, two groups of categorized factors were analyzed – clinical (sex, age, form of AF, etc.) and pharmacological (use of different classes of drugs). The necessary information was obtained from outpatient cards analyzed when patients were included in the study.

Results. The survival rate of patients with AF was significantly (p<0.05-0.001) influenced by the following factors and their categories: age (<60 years – 92.5%, 60-65 years – 92.9%, over 75 years – 80.1%); AF form (paroxysmal – 95.1%, persistent – 93.2%, permanent – 84.4%); stable angina (SA) (presence – 86.5%, absence – 90.7%); chronic heart failure functional class (CHF FC) (I-II – 95.9%, III – 91.5%, IV – 69.6%); glomerular filtration rate (GFR) (>50 ml/min – 89.6%, 30-50 ml/min – 85.8%, <30 ml/min – 72.7%); diabetes mellitus (DM) (presence – 81.9%, absence – 90.4%), hospitalization for the year preceding inclusion in the study (presence – 85.5%, absence – 97.3%), the use of oral anticoagulants (OAC) (presence – 96.7%, absence – 87.1%). In subgroups of patients with the above mentioned categories (especially the most severe) of the studied factors, significant (p<0.05-0.01) differences in the proportion of surviving patients depending on the appointment of OAC were revealed: age >75 years – 78.2% and 100%; permanent form of AF – 81.9% and 96.1%, the presence of SA – 85.0% and 94.7%; CHF FC IV – 67.0% and 91.7%; GFR<30 ml/min – 62.5% and 100%; presence of DM – 80.7% and 88.2%.%; the presence of hospitalizations in the last year – 82.9% and 97.2%; >5 points on the CHA2DS2VASc scale – 67.0% and 91.7%, heart rate >90/min – 68.8% and 100% of patients with the absence and presence of the OAC therapy, respectively. Cox regression analy sis revealed clinical predictors contributing to an increase in the risk of death: age over 75 years, permanent form of AF, CHF FC III-IV, the presence of DM, the presence of previous hospitalizations. The absence of the OAC taking was accompanied by an increase in the risk of death by 3.66 times.

Conclusion. The results of the REKUR-AF study allowed to establish the most significant factors affecting the survival of patients with AF: age, form of AF, CHF FC, presence of DM, hospitalization in the last year preceding the inclusion of patients in the study, OAK taking. The prescription of OAC is a priority predictor that improves survival in patients with AF. 

About the Authors

I. L. Polshakova
Kursk State Medical University
Russian Federation

MD, Assistant, Chair of Clinical Pharmacology,

Karla Marksa ul. 3, Kursk, 305041 



S. V. Povetkin
Kursk State Medical University
Russian Federation

MD, PhD, Professor, Head of Department of Clinical Pharmacology, 

Karla Marksa ul. 3, Kursk, 305041 



References

1. Atrial fibrillation and flutter. Clinical recommendations of ACVS (2017). [cited by May 27, 2019]. Available from: https://racvs.ru/clinic/files/2018/rek_fp.pdf. (In Russ.)

2. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. DOI:10.1093/eurheartj/ehw210.

3. Podzolkov V.I., Tarzimanova A.I. Current predictors of atrial fibrillation progression. Rational Pharmacotherapy in Cardiology. 2019;15(2);149-58. (In Russ.) DOI:10.20996/1819-6446-2019-15-2-149-158.

4. Martsevich S.Y., Kutishenko N.P., Suvorov A.V. et al. The main factors affecting the long-term outcomes in patients after acute cerebrovascular disorder: results of the LIS-2 study. Rational Pharmacotherapy in Cardiology. 2016;12(1);51-5 (In Russ.) DOI:10.20996/1819-6446-2016-12-1-51-55.

5. Polshakova I.L., Povetkin S.V. The register of patients with atrial fibrillation in Kursk region (RECURAF): design and research strategy. Kursk Scientific and Practical Bulletin "Man and His Health". 2017;4;19-22 (In Russ.) DOI:10.21626/vestnik/2017-4/03.

6. Polshakova I.L., Povetkin S.V. Drug therapy structure and clinical characteristics of patients with atrial fibrillation according to data of REKUR-AF study. Rational Pharmacotherapy in Cardiology. 2018;14(5);733-740. (In Russ.) DOI:10.20996/1819-6446-2018-14-5-733-740.

7. Glantz S. Medico-biological statistics. Moscow: Practice; 1999. (In Russ.).

8. Sharashova E.E., Kholmatova K.K., Gorbatova M.A., Grjibovski A.M. Cox regression in health sciences using SPSS software. Science and Healthcare. 2017;6:5-27 (In Russ.).

9. Sharashova E.E., Kholmatova K.K., Gorbatova M.A., Grjibovski A.M. Survival analysis in health sciences using SPSS software. Science and Healthcare. 2017;5:5-28 (In Russ.).

10. Boytsov S.A., Lukyanov M.M, Yakushin S.S., et al. The outpatient based registry RECVASA: prospective follow-up data, risk evaluation and outcomes in cardiovascular patients. Cardiovascular Therapy and Prevention. 2015;14(1):53-62 (In Russ.) DOI:10.15829/1728-8800-2015-1-53-62.

11. Mikhin V.P., Maslennikova Y.V., Lukyanov M.M., et al. Structure of mortality and evaluation of death risk in patients with combination of atrial fibrillation and coronary heart disease (RECVASA AF-Kursk registry data). Kursk Scientific and Practical Bulletin “Man and His Health”. 2017;4;35-41 (In Russ.) DOI:10.21626/vestnik/2017-4/07.

12. Kodani E., Atarashi H., Inoue H. et al. Impact of creatinine clearance on outcomes in patients with non-valvular atrial fibrillation: a subanalysis of the J-RHYTHM Registry. Eur Heart J Qual Care Clin Outcomes. 2018;4(1):59-68. DOI:10.1093/ehjqcco/qcx032.

13. Wang L., Du X., Dong J.Z. et al. Body mass index and all-cause mortality in patients with atrial fibrillation: insights from the China atrial fibrillation registry study. Clin Res Cardiol. 2019. DOI:10.1007/s00392-019-01473-3.

14. Rodriguez-Manero M. Lopez-Pardo E., Cordero A., et al. A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chron Obstruct Pulmon Dis. 2019;14:371-380. DOI:10.2147/COPD.S174443.


For citation:


Polshakova I.L., Povetkin S.V. Comparative Analysis of Factors Affecting the Prognosis of Patients with Atrial Fibrillation According to the Results of the REKUR-AF Study. Rational Pharmacotherapy in Cardiology. 2019;15(5):649-655. (In Russ.) https://doi.org/10.20996/1819-6446-2019-15-5-649-655

Views: 23


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)